Dubois-Stringfellow Nathalie (CIK 1947007) reported 11 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-05-27). Recent activity: Sell SGMO (4,036 shares), Sell SGMO (345,942 shares), Sell SGMO (2,063 shares), Sell SGMO (12,354 shares), Sell SGMO (36,676 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-27 | SANGAMO THERAPEUTICS, INC (SGMO) | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 4,036 | $703 |
| 2026-04-23 | SANGAMO THERAPEUTICS, INC (SGMO) | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 345,942 | $89,184 |
| 2026-02-26 | SANGAMO THERAPEUTICS, INC (SGMO) | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 2,063 | $970 |
| 2026-02-26 | SANGAMO THERAPEUTICS, INC (SGMO) | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 12,354 | $5,806 |
| 2026-01-26 | SANGAMO THERAPEUTICS, INC (SGMO) | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 36,676 | $14,670 |
| 2025-11-26 | SANGAMO THERAPEUTICS, INC (SGMO) | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 2,544 | $1,068 |
| 2025-10-24 | SANGAMO THERAPEUTICS, INC (SGMO) | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 43,741 | $28,869 |
| 2025-08-26 | SANGAMO THERAPEUTICS, INC (SGMO) | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 1,792 | $1,057 |
| 2025-07-24 | SANGAMO THERAPEUTICS, INC (SGMO) | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 31,866 | $15,296 |
| 2025-05-28 | SANGAMO THERAPEUTICS, INC (SGMO) | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 1,792 | $842 |
| 2025-04-24 | SANGAMO THERAPEUTICS, INC (SGMO) | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 31,866 | $24,855 |
Source: SEC Form 4 filings · as of 2026-05-27